Vitality Biopharma (OTCMKTS:VBIO) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
This is a summary of current recommendations and price targets for Vitality Biopharma and Exelixis, as reported by MarketBeat.com.
||Strong Buy Ratings
Exelixis has a consensus target price of $28.43, suggesting a potential upside of 47.76%. Given Exelixis’ higher possible upside, analysts plainly believe Exelixis is more favorable than Vitality Biopharma.
Volatility & Risk
Vitality Biopharma has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.
Insider & Institutional Ownership
0.2% of Vitality Biopharma shares are held by institutional investors. Comparatively, 77.4% of Exelixis shares are held by institutional investors. 8.7% of Vitality Biopharma shares are held by insiders. Comparatively, 4.5% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Vitality Biopharma and Exelixis’ gross revenue, earnings per share and valuation.
||Earnings Per Share
Exelixis has higher revenue and earnings than Vitality Biopharma.
This table compares Vitality Biopharma and Exelixis’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Exelixis beats Vitality Biopharma on 8 of the 11 factors compared between the two stocks.
About Vitality Biopharma
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions. It develops additional cannabinoid product formulations for refractory pain and autism spectrum disorder. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. The company was founded in 2007 and is based in Los Angeles, California.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.